November 1, 2011European Journal of Cardio-Thoracic Surgery
Trans-apical aortic valve implantation using a new self-expandable bioprosthesis: initial outcomes
Why the study?
Is trans-apical aortic valve implantation using the Symetis Acurate self-expandable bioprosthesis safe and effective in high-risk elderly patients?
Population
40 high-risk, elderly patients requiring aortic valve implantation with an annular diameter between 21 and…
Design
Case_series
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Early experience indicates procedural feasibility; leaves open need for larger trials on safety and durability.
Structured PICO
Is trans-apical aortic valve implantation using the Symetis Acurate self-expandable bioprosthesis safe and effective in high-risk elderly patients?
P
Population
40 high-risk, elderly patients requiring aortic valve implantation with an annular diameter between 21 and 27mm, mean age 82.8±4 years, 60% female.
I
Intervention
Trans-apical aortic valve implantation using the Symetis Acurate self-expandable bioprosthesis (porcine biologic valve attached to a self-expandable nitinol stent).
O
Outcome
Procedural success, mortality, complications, and echocardiographic outcomes (aortic incompetence, transvalvular gradients) at 30 days.safety
The Symetis Acurate self-expandable bioprosthesis demonstrates feasible implantation and acceptable initial functional results for trans-apical aortic valve replacement in high-risk patients.
Cite This Study
Kempfert et al. (2011) studied this question.